Swedish Orphan Biovitrum
281 SEK +0.07%3 investors are following this company
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Revenue
22.12B
EBIT %
18.38 %
P/E
37.62
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SOBI
Daily low / high price
269.2 / 286.8
SEK
Market cap
99.57B SEK
Turnover
314.71M SEK
Volume
1.1M
Financial calendar
General meeting
14.05.2024
Interim report
16.07.2024
Interim report
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Investor | 34.7 % | 34.7 % |
Morgan Stanley Smith Barney | 9.9 % | 9.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Swedish Orphan Biovitrum AB: Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Swedish Orphan Biovitrum AB: Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools